• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Orhub's Ryan Fernan Becomes Head Of Pur Biologics, Leading Regenerative Therapeutic Efforts

    7/27/22 2:30:00 PM ET
    $BAX
    $HSTO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BAX alert in real time by email

    A proven industry leader and executive, Ryan Fernan, will help ORHub advance Ortho-Spine technology beyond current limitations.

    IRVINE, CA / ACCESSWIRE / July 27, 2022 / ORHub, Inc. (OTC:ORHB) officially kicks off the acquisition of PUR Biologics ("PUR") with the appointment of Ryan Fernan as the Head of PUR Biologics. An ORHub biotech company, PUR Biologics is focused on delivering next generation regenerative biologic products to address degenerative musculoskeletal diseases.

    Mr. Fernan, brings direct access to a broad industry network with a proven track record of over 18 years in the medical device and biotechnology industry. Recognized as a frontrunner in sales and product development, Mr. Fernan's career included leadership roles associated with Johnson&Johnson/DePuy Spine, and then Zimmer/Biomet. With a strong entrepreneurial drive, Mr. Fernan also founded OC Surgical, Inc., which became the largest Actifuse distributor in the United States from UK-based orthobiologics company, ApaTech. His successes with Actifuse largely contributed to its purchase by Baxter (NYSE:BAX) for approx. $330M in 2010. Mr. Fernan went on to found PUR Biologics, quickly developing technologies from concept, through pre-clinical trials, to large animal trials in collaboration with the University of Colorado and UCSD, and into initial FDA human clinical trial discussions. These first- generation technologies were negotiated into a successful sale by Mr. Fernan to Histogen, Inc. (NASDAQ:HSTO), while he continued directing the licensing and development of the next generation of cell derived extracellular matrix technologies.

    "Mr. Fernan has already hit the ground running, identifying multiple technologies which we are evaluating for acquisition or licensing," said CJ Wiggins - ORHub Founder, Executive Chairman & CEO. "Our intention with these potential deals is to place PUR in a leading position of today's bone growth market and tomorrow's advanced ortho-spine solutions. I am proud to have Ryan lead our Regenerative Therapeutic efforts and am excited by the plans to change how unmet patient needs will be addressed."

    "I am focused on significantly improving clinical outcomes, while generating revenue, and have already secured many strategic sales opportunities. We are now completing our industry leading portfolio of advanced ortho-spine biologics," added Ryan Fernan, new Head of PUR Biologics. "We will be aligning with key opinion and industry leaders, who will support our highly innovative products and in turn, assist us in developing our new cell derived technologies addressing the osteoarthritis, cartilage regeneration, and the mitigation of pain."

    With PUR's proprietary technologies, market access, and proven track record in product development, ORHub's Regenerative Therapeutic division is poised to impact multiple therapy markets that exceed a combined $40B in annual revenue.

    --------------

    About ORHub, Inc.
    ORHub, Inc. is headquartered in Irvine, California. The Company is a healthcare innovator and fintech company focused on payment processes, business logistics, and clinical solutions with digital and biological technologies. The Company utilizes Intelligent Automation and Cellular based technologies to Change Business for GoodTM and is comprised of four segments: Surgical Resource Management (SRM), Digital Payments, Regenerative Therapeutics, and Artificial Intelligence:

    ORHub's SRM platform, "FutureOR" uses digital technologies to replace dated vendor-centric documentation and processes. The platform enables digital connectivity, faster vendor payments, and implant accountability for all surgically implanted medical devices and biologic products. The Company's Digital Payment focus is on software solutions which would allow b2b medical device & biologic vendors to reduce the Case-to-Cash timeline. With the acquisition of PUR Biologics, ORHub's Regenerative Therapeutic division is focused on the sale of bone regenerative products, while targeting new areas of opportunity with patented cell-based technologies. Together, these solutions form a valuable foundation for new uses of AI, quantum computing, and a mobile ecosystem for personalized patient centered information and accessibility.

    For more information, please visit: ORHub.com

    ###

    Forward-looking Statements

    This release contains forward-looking statements, including the market demand for and acceptance of ORHub's products and services, the results from use of ORHub's products and services, and general business conditions, particularly within the surgical, life science, and medical device industries. Any forward-looking statements contained in this press release are based upon ORHub's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ORHub's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Further information on potential risks that could affect actual results will be included in future filings made by ORHub and are available on the Company's website at ORHub.com from time to time.

    Contact:

    Jason Brown
    ORHub, Inc.
    612-209-7565

    SOURCE: ORHUB, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/709996/Orhubs-Ryan-Fernan-Becomes-Head-Of-Pur-Biologics-Leading-Regenerative-Therapeutic-Efforts

    Get the next $BAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BAX
    $HSTO

    CompanyDatePrice TargetRatingAnalyst
    Baxter International Inc.
    $BAX
    2/26/2025$42.00Buy
    Goldman
    Baxter International Inc.
    $BAX
    2/24/2025Hold → Buy
    Argus
    Baxter International Inc.
    $BAX
    2/20/2025$39.00Overweight
    Barclays
    Baxter International Inc.
    $BAX
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    Baxter International Inc.
    $BAX
    5/30/2024$36.00Neutral
    Goldman
    Baxter International Inc.
    $BAX
    5/10/2024$40.00Buy → Hold
    TD Cowen
    Baxter International Inc.
    $BAX
    5/30/2023$45.00Equal-Weight
    Morgan Stanley
    Baxter International Inc.
    $BAX
    3/29/2023$43.00Neutral
    UBS
    More analyst ratings

    $BAX
    $HSTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Baxter Declares Quarterly Dividend

      Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on July 1, 2025, to stockholders of record as of May 30, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovat

      5/6/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter Reports First-Quarter 2025 Results

      First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company's previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company's previously issued guidance Baxter increases bottom end of previous range for full-year 2025 adjusted diluted EPS guidance and now expects adjusted diluted EPS of $2.47 to $2.551 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. "Our solid performance in the first quarter of

      5/1/25 7:15:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter to Present at Bank of America Securities 2025 Health Care Conference

      Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:40 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Sunday, November 9, 2025. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years

      4/29/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    $HSTO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 18, 2024 - FDA Roundup: October 18, 2024

      For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

      10/18/24 4:16:25 PM ET
      $NVCR
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    $HSTO
    SEC Filings

    See more
    • Baxter International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      5/8/25 4:15:37 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Baxter International Inc.

      10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      5/6/25 4:34:41 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      5/1/25 7:17:51 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    $HSTO
    Financials

    Live finance-specific insights

    See more
    • Baxter Declares Quarterly Dividend

      Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on July 1, 2025, to stockholders of record as of May 30, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovat

      5/6/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter Reports First-Quarter 2025 Results

      First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company's previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company's previously issued guidance Baxter increases bottom end of previous range for full-year 2025 adjusted diluted EPS guidance and now expects adjusted diluted EPS of $2.47 to $2.551 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. "Our solid performance in the first quarter of

      5/1/25 7:15:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter to Host First-Quarter 2025 Financial Results Conference Call for Investors

      Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2025 financial results on Thursday, May 1, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I763359 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on B

      4/15/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    $HSTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

      SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

      11/13/24 1:08:27 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

      SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

      2/13/24 5:00:53 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Baxter International Inc.

      SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

      2/13/24 1:08:57 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    $HSTO
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Baxter Appoints Jeffrey A. Craig to Its Board

      Addition of Mr. Craig complements current board expertise with deep financial, broad operational and public company board experience Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter's Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12. "We are excited to welcome Jay to Baxter's board," said José (Joe) E. Almeida, chair, president and CEO. "As a former CEO, CFO, COO and public company auditor, Jay's broad-based busin

      9/9/24 9:00:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    $HSTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wilkes David S. was granted 7,183 shares, increasing direct ownership by 43% to 23,906 units (SEC Form 4)

      4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

      5/8/25 4:29:28 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Director Wendell Amy Mcbride was granted 7,183 shares, increasing direct ownership by 30% to 31,222 units (SEC Form 4)

      4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

      5/8/25 4:28:59 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Director Smith Cathy R was granted 7,183 shares, increasing direct ownership by 31% to 30,345 units (SEC Form 4)

      4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

      5/8/25 4:28:20 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    $HSTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman resumed coverage on Baxter with a new price target

      Goldman resumed coverage of Baxter with a rating of Buy and set a new price target of $42.00

      2/26/25 7:01:30 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter upgraded by Argus

      Argus upgraded Baxter from Hold to Buy

      2/24/25 10:10:46 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Barclays resumed coverage on Baxter with a new price target

      Barclays resumed coverage of Baxter with a rating of Overweight and set a new price target of $39.00

      2/20/25 8:18:14 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care